Exelixis Inc at Jefferies London Healthcare Conference Transcript
Good day, everyone. Day 2 of our health care conference. For those who don't know me. My name is Akash Tewari. I am one of the therapeutic analysts here at Jefferies. I have the pleasure of hosting Andrew Peters, Senior Vice President and Head of Strategy at Exelixis. Andrew is very happy that he's not on this side anymore having started his own companies.
(technical difficulty)
for some brief introductory remarks, and then we'll get into some more specifics. Go ahead.
Yes. Thanks for having me, and thanks for the invite. Just before I start, I'd like to say, likely going to be some -- making some forward-looking statements today. So please see our SEC filings for necessary risks to our business.
So Exelixis is a commercial-stage oncology company. Our lead product, cabozantinib, commercial name CABOMETYX, approved in RCC and a couple of other different tumor types, on market now giving guidance for 2022 revenue of $1
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
